Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Transvenous Chemoembolization of Primary Pancreatic Tumors

NCT03865563 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT03865563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 1
Overall status
Withdrawn
Start date
July 31, 2019
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma